Navigation Links
Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
Date:5/21/2008

- Innovative pipeline products highlight Watson's commitment to urology -

Embargoed Until 2:10 PM EDT

ORLANDO, Fla., May 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that investigators presented clinical data on two Phase 3 products at the American Urological Association's annual meeting. The abstracts include a cardiac safety trial involving silodosin, an investigational treatment for benign prostatic hyperplasia (BPH, or prostate enlargement) and a pharmacokinetic study of oxybutynin chloride topical gel (OTG), an investigational product for overactive bladder.

"Watson is committed to helping urologists offer their patients the highest standard of care through providing novel treatments that continually address areas of urology with limited therapeutic options," said Edward Heimers, Jr., Executive Vice President and President of Watson's Brand Division. "We are extremely encouraged by the results demonstrated in these two trials, as they support the safety of silodosin and the potential efficacy of OTG as well as offer important patient benefits. A marketing application for silodosin has been filed with the FDA, and one for OTG will be filed. Both products represent potentially important additions to the expanding Watson urology franchise."

In the first trial (abstract #2037), investigators conducted a double-blind, randomized, parallel-group trial to assess whether or not silodosin -- an investigational alpha blocker -- would prolong the QT interval on an electrocardiogram (ECG). QT is a measure of the heart's electrical activity. A prolongation of the QTc (corrected for heart rate) interval favors the develo
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Launches Generic Biaxin(R) XL
4. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
5. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
6. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
7. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
8. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
9. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
10. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
11. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 The Pulmonary Fibrosis Foundation (PFF) ... more than 1,100 patients and families suffering from pulmonary ... (FDA) for the Patient-Focused Drug Development Meeting for Idiopathic ... FDA initiative to seek patient input in order to ... "We applaud the FDA for focusing its ...
(Date:9/16/2014)... 2014 Chindex International, Inc. ("Chindex" or the ... a special meeting of stockholders held today, the Company,s ... Agreement") by and among the Company, Healthy Harmony Holdings, ... Parent is an affiliate of TPG, Shanghai Fosun Pharmaceutical ... , the CEO of the Company. The ...
(Date:9/16/2014)... /PRNewswire-iReach/ -- Dan York has been named ... the RTD ® Advanced Wound Care Dressing, as ... presence in the U.S. Under York,s leadership, GWM Products, ... sales representatives in new sales territories that will complement ... up to 20 sales representatives in major metropolitan areas ...
Breaking Medicine Technology:PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 2PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 3PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 4Chindex Stockholders Approve Merger 2Chindex Stockholders Approve Merger 3GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2
... studies including a pivotal Phase III trial in patients,with ... tablets will be presented at the Annual,Meeting of the ... June 1 - 5, 2007. , On this occasion ... on June 4, 2007. Starting at around 2:00 p.m. ...
... of Eisai's,Commitment to Oncology, WOODCLIFF LAKE, N.J., May ... abstracts covering clinical data about,their oncology pipeline compounds ... of Clinical Oncology (ASCO),annual meeting. ASCO takes place ... reveal a growing and diverse oncology clinical,development program ...
Cached Medicine Technology:Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 2Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 3Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 4
(Date:9/16/2014)... WASHINGTON, DC September 14, 2014 A ... provisional side branch (SB) stenting of true coronary ... standard of care. The DKCRUSH-VI clinical trial is ... stenting. , Findings were reported today at ... symposium. Sponsored by the Cardiovascular Research Foundation (CRF), ...
(Date:9/16/2014)... therapy and radiation therapy as part of breast ... women with hormone-receptor positive (HR+) invasive breast cancer. ... Cancer Center, however, shows that combination may not ... disease. , The results, which Fox Chase ... Oncology,s 56th Annual Meeting on Sunday, September 14, ...
(Date:9/16/2014)... that corn absorbs the right balance of nitrogen, phosphorus ... Purdue and Kansas State University study finds. , A ... the U.S. and other regions showed that high yields ... took up key nutrients at specific ratios - nitrogen ... and potassium at a ratio of 1-to-1. These nutrient ...
(Date:9/16/2014)... Seven heroes who have dramatically improved the ... in New York City on November 6 by World ... recognition and funding program that honors individuals serving vulnerable ... the “Nobel Prize for Child Advocates,” this year’s selection ... benefit children in countries around the world dealing with ...
(Date:9/16/2014)... Who:, The Pulmonary Hypertension Association (PHA), ... Children’s Hospital Colorado are hosting Colorado PH in the ... association that works to find ways to prevent and cure ... affects the functioning of the heart and can lead to ... years. , What:, Colorado PH in the Park 2014 ...
Breaking Medicine News(10 mins):Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:Boosting global corn yields depends on improving nutrient balance 2Health News:Boosting global corn yields depends on improving nutrient balance 3Health News:World of Children® Award Announces 2014 Honorees 2Health News:World of Children® Award Announces 2014 Honorees 3Health News:World of Children® Award Announces 2014 Honorees 4Health News:World of Children® Award Announces 2014 Honorees 5Health News:World of Children® Award Announces 2014 Honorees 6Health News:World of Children® Award Announces 2014 Honorees 7Health News:World of Children® Award Announces 2014 Honorees 8Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2
... A new study shows that estrogen therapy does not ... postmenopausal women, say researchers //.Previous studies have reported an ... dementia. ,A placebo-controlled trial of estrogen or estrogen ... looked at associated risk for dementia. In the estrogen-only ...
... in your 20s could reduce the risk of developing high ... psychological stress with spikes in blood pressure are more likely ... 40s. ,Specialists say assessing blood pressure changes in response ... person’s future risk of high blood pressure. In a large ...
... shows dogs may be able to anticipate seizures in ... dogs in this study was // licking, often ... and “protective" behavior without aggression. In previous studies, owners ... even prevent their seizures. Some breeds of seizure-alerting ...
... patients consume about 40 milligrams of vitamin C daily ... vitamin C may protect against rheumatoid arthritis. ,Researchers ... 45 and 74. Participants' diets were assessed by using ... in two or more joints for at least one ...
... with a number of other side effects. For some people ... through with it may not even get rid of their ... to delivering chemotherapy. ,Perfusion therapy is the most aggressive ... avoid the toxicity to the rest of the body .Blood ...
... might help protect the eyes against a leading cause of ... // men and women it was found that those ... had a 36-percent lower risk of developing age-related maculopathy than ... have linked consumption of antioxidant vitamins and minerals to lower ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: